The Latest Breaking News from Royalty Pharma

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

A Relative Strength Rating upgrade for Royalty Pharma shows improving technical performance.

Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed.

Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock broke out at the open.

Warren Buffett is arguably the world’s most famous investor, and his investment moves are closely followed. Each quarter, the company he runs, Berkshire Hathaway, discloses its current holdings to shareholders.

Today Blueprint Medicines Corp (NASDAQ:BPMC) announced strategic financing agreements with Sixth Street and Royalty Pharma Plc (NASDAQ:RPRX) for up to $1.25 billion, including $575 million upfront upon deal closure. SVB Securities thinks the terms of the deals are fairly valued on the Sixth Street portion and favorable for Blueprint Medicines on the Royalty Pharma portion. "In addition,…

Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter:

Upgrades

Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters.